Royce & Associates’s Coherus Oncology CHRS Stock Holding History

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-106,700	Closed	-$399K	–	875
2023 Q3	$399K	Hold	106,700	–	–	﹤0.01%	831
2023 Q2	$456K	Hold	106,700	–	–	﹤0.01%	848
2023 Q1	$730K	Hold	106,700	–	–	0.01%	807
2022 Q4	$845K	Sell	106,700 -2,577	-2%	-$19.8K	0.01%	777
2022 Q3	$1.05M	Sell	109,277 -12,507	-10%	-$127K	0.01%	729
2022 Q2	$882K	Sell	121,784 -21,163	-15%	-$184K	0.01%	768
2022 Q1	$1.84M	Buy	142,947 +94,318	+194%	+$1.2M	0.02%	723
2021 Q4	$776K	Sell	48,629 -98,394	-67%	-$1.72M	0.01%	836
2021 Q3	$2.36M	Buy	147,023 +18,386	+14%	+$269K	0.02%	720
2021 Q2	$1.78M	Buy	128,637 +1,164	+0.9%	+$16.5K	0.01%	774
2021 Q1	$1.86M	Sell	127,473 -212,999	-63%	-$3.62M	0.01%	763
2020 Q4	$5.92M	Sell	340,472 -30,042	-8%	-$535K	0.05%	513
2020 Q3	$6.79M	Buy	370,514 +14,899	+4%	+$277K	0.07%	398
2020 Q2	$6.35M	Buy	355,615 +57,103	+19%	+$967K	0.07%	398
2020 Q1	$4.84M	Buy	+298,512	New	+$5.52M	0.07%	386